Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bmj.g4616 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Iron deficiency anaemia in a stable chronic intestinal failure cohort: Prevalence, associations and outcomes.
Clin Nutr ESPEN
January 2025
Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK; School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.
Background & Aims: Current estimates of the prevalence of iron deficiency anaemia (IDA) in patients with chronic intestinal failure (CIF) exceed those seen in general population, however, the studies to-date are limited. The aim of this study was to determine the point prevalence of IDA in a large cohort of stable home parenteral nutrition (HPN) dependent adults managed by a specialist Intestinal Failure Unit.
Methods: This was a retrospective cohort study of HPN-dependent adults managed by a national UK IF Reference Centre between 01/01/2019 and 31/12/2019.
The Intersection of Heart Failure and Iron Deficiency Anemia: Diagnostic and Therapeutic Approaches.
Curr Cardiol Rev
January 2025
Shri Venkateshwara University, Gajraula, Uttar Pradesh, India.
Iron deficiency anemia (IDA) is highly prevalent among individuals with heart failure (HF), impacting 40-70% of patients and serving as a significant prognostic indicator. Linked with oxidative metabolism and myocardial cell damage, IDA exacerbates HF symptoms, including reduced exercise capacity, diminished quality of life, and heightened cardiovascular morbidity. This review explores the diagnosis, treatment, clinical outcomes, prognostic indicators, and forthcoming challenges associated with IDA in HF patients.
View Article and Find Full Text PDFIntravenous iron sucrose when administered to moderately anemic pregnant women raises the hemoglobin concentration and replenishes body iron at 6 months.
J Family Med Prim Care
November 2024
Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India.
Introduction: Intravenous iron sucrose (IVIS) is a rapidly acting, safe, and effective treatment for moderate anemia among pregnant women. The effectiveness of IVIS at 6 months post IVIS infusion was unknown. We, therefore, assessed the mean increase in hemoglobin concentration and body iron replenishment status at 6 months after the last dose of IVIS infusion.
View Article and Find Full Text PDFRecurrent Hypophosphatemia Following a Single Dose of Parenteral Iron Administration.
Cureus
November 2024
Acute Medicine, Royal Stoke University Hospital, Stoke-on-Trent, GBR.
Although parenteral iron is widely used to treat iron deficiency anemia (IDA), some side effects have been inadequately explored. Hypophosphatemia is becoming a well-documented, yet poorly understood, side effect of parenteral iron infusion, oftentimes causing serious and/or prolonged complications. In this article, we discuss the case of a 33-year-old female with IDA who suffered debilitating physical and mental symptoms of significant recurrent hypophosphatemia following a single standard dose of parenteral iron administration.
View Article and Find Full Text PDFRoxadustat Efficacy and Safety in Patients Receiving Peritoneal Dialysis: Pooled Analysis of Four Phase 3 Studies.
J Clin Med
November 2024
Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8666, Japan.
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved to treat anemia of chronic kidney disease (CKD). The efficacy and safety of roxadustat compared with parenteral erythropoiesis-stimulating agents (ESAs) were evaluated in patients with anemia of CKD receiving peritoneal dialysis (PD). This analysis pooled data from four phase 3, multicenter, randomized, open-label, active-comparator studies (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!